ClinicalTrials.gg
CompletedNCT01649557STEP 210Updated Oct 29, 2015Results posted

Multicenter, Open-label, Safety and Tolerability Study

A Phase 2 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 71 sites in 12 countries. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
244
Allocation
Not applicable
Ages
18 Years to 67 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
12th of 28
244 · median 155
Started
2009
with 1 other
Phase 2
2 of 28
none open now
Registered
11th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 12th largest by enrollment, is one of 2 that started in 2009, is one of 2 in phase 2, and was the 11th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 67 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis. Enrollment into the study will be drawn from eligible subjects who have completed participation in Study 331-07- 203 and who, in the investigator's judgment, would benefit from continued treatment with oral OPC-34712.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who participated in 331-07-203 and who, in the opinion of the investigator, have the potential to benefit from continued administration of OPC-34712 for the treatment of schizophrenia.
  2. Outpatient status at last visit of Study 331-07-203.

Exclusion criteria

Exclusion Criteria:

  1. Sexually active males who are not practicing two different methods of during the study and for 90 days after the last dose of study medication or who will not remain abstinent during the study and for 90 days after the last dose, or sexually active females of who are not practicing two different methods of birth control during the study and for 30 days after the last dose of study medication or who will not remain abstinent during the study and for 30 days after the last dose. If employing birth control, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injection, birth control implant, condom, or sponge with spermicide.
  2. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving open-label OPC-34712.
  3. Subjects who during the course of their participation in 331-07-203 were treated in violation of the protocol or who developed ANY exclusion criteria during the course of their participation.
  4. Subjects who do not continue to meet all applicable inclusion/exclusion criteria for Protocol 331-07-203 at the last visit (ie, Week 6) of Protocol 331-07-203.
  5. Subjects who represent a risk of committing suicide based on an answer of "Yes" to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or an answer of "Yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior) on the "Suicidal Behavior" portion of the C-SSRS. A subject who has had any suicidal ideation within the last 6 months, any suicidal behaviors within the last two years, or who in the clinical judgment of the investigator presents a serious risk of suicide should be excluded from the study.
  6. Subjects who would be likely to require prohibited concomitant therapy during the study.
  7. Any subject who, in the opinion of the investigator, should not participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Open-label OPDC-34712

    Drug: OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) During First 6 Weeks.

    AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

    Time frame: From Baseline up to 6 weeks

  2. Number of Participants With AEs in 52-Week Enrollers.

    AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A SAE was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A TEAE was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

    Time frame: From Baseline up to 52 weeks

Secondary outcomes

  1. Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) by Study Week and at the Last Visit.

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. The PANSS total score ranges from 30-210, with higher scores indicating more severe symptoms.

    Time frame: Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit

  2. Change From Baseline in Clinical Global Impression- Severity of Illness Scale (CGI-S) Score.

    The severity of illness for each participant were rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit

  3. Change From Baseline in Personal and Social Performance Scale (PSP) Total Score.

    The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: Baseline, Week 1, 2, 6, 26, 52 and Last Visit

  4. Mean Clinical Global Impression- Improvement Scale (CGI-I) Total Score.

    The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participants total improvement whether or not it was due to the drug treatment. All responses were compared to the participants condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit

  5. Change From Baseline in PANSS Positive Subscale Score.

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive symptom score ranges from 7-49, with higher scores indicating more severe symptoms.

    Time frame: Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit

  6. Change From Baseline in PANSS Negative Subscale Score.

    The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative symptom score ranges from 7-49, with higher scores indicating more severe symptoms.

    Time frame: Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit

  7. Percentage of Participants With a Positive Response Rate.

    Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.

    Time frame: Last Visit

  8. Percentage of Participants Who Discontinued Due to Lack of Efficacy.

    Discontinuation rate for the participants discontinued due to lack of efficacy were examined.

    Time frame: Last Visit

07

Results

Posted Oct 29, 2015

Participant flow

The protocol was initially approved as a 6-week trial and later extended to a 52-week trial (Amendment 2). The trial enrolled 244 participants at 73 sites in 12 countries. Of the 244 participants, 28 were included in the 52-week enrollment population.

Participant flow — Overall Study
MilestonePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Started1794124
6-week enrollers1593522
52-week enrollers2062
Completed1352715
Not completed44149
Withdrew: Lost to follow-up503
Withdrew: Adverse event751
Withdrew: Met withdrawal criteria400
Withdrew: Physician decision821
Withdrew: Withdrawal by subject1554
Withdrew: Protocol deviation020
Withdrew: Lack of efficacy500

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) During First 6 Weeks.

AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

Time frame:
From Baseline up to 6 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) During First 6 Weeks.
ParticipantsPrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Participants with AEs79197
Participants with TEAEs78197
Participants with serious TEAEs461
Participants with severe TEAEs232
PrimaryNumber of Participants With AEs in 52-Week Enrollers.

AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A SAE was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A TEAE was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication.

Time frame:
From Baseline up to 52 weeks
Reported as:
Number · Participants
Number of Participants With AEs in 52-Week Enrollers.
ParticipantsPrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Participants with AEs1542
Participants with TEAEs1542
Participants with serious TEAEs000
Participants with severe TEAEs010
SecondaryChange From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) by Study Week and at the Last Visit.

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. The PANSS total score ranges from 30-210, with higher scores indicating more severe symptoms.

Time frame:
Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit
Reported as:
Mean · Units on a scale
Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) by Study Week and at the Last Visit.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Day 4 (N= 169, 36, 22)0.11 ± 5.86-1.25 ± 3.97-1.50 ± 4.97
Week 1 (N= 167, 40, 23)-2.03 ± 5.49-1.53 ± 7.95-1.91 ± 6.22
Week 2 (N= 165, 40, 21)-2.95 ± 8.80-3.43 ± 10.68-1.86 ± 6.04
Week 4 (N=148, 34, 18)-4.65 ± 8.59-4.71 ± 12.85-5.39 ± 6.30
Week 6 (N= 138, 31, 15)-7.51 ± 8.82-7.87 ± 10.26-7.47 ± 7.22
Week 8 (N=20, 6, 2)-8.80 ± 8.69-5.17 ± 7.55-10.00 ± 1.41
Week 14 (N=20, 6, 2)-9.85 ± 8.096.83 ± 28.29-3.50 ± 12.02
Week 20 (N= 20, 5, 2)-10.20 ± 9.12-4.60 ± 10.71-6.50 ± 10.61
Week 26 (N= 19, 5, 2)-12.89 ± 9.34-5.80 ± 11.56-10.50 ± 7.78
Week 32 (N= 18, 5, 2)-14.67 ± 10.94-3.00 ± 16.90-16.00 ± 0.00
Week 38 (N= 17, 3, 2)-13.24 ± 10.97-4.67 ± 10.21-13.00 ± 0.00
Week 44 (N= 17, 2, 2)-16.00 ± 10.28-4.50 ± 12.02-11.50 ± 2.12
Week 52 (N= 16, 2, 2)-15.00 ± 10.06-5.50 ± 13.44-11.00 ± 7.07
Last visit (N= 176, 41, 23)-5.99 ± 11.25-2.32 ± 18.97-5.96 ± 8.27
SecondaryChange From Baseline in Clinical Global Impression- Severity of Illness Scale (CGI-S) Score.

The severity of illness for each participant were rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression- Severity of Illness Scale (CGI-S) Score.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Day 4 (N= 169, 36, 22)0.02 ± 0.51-0.03 ± 0.290.05 ± 0.38
Week 1 (N= 167, 40, 23)-0.08 ± 0.47-0.05 ± 0.60-0.04 ± 0.37
Week 2 (N= 164, 40, 21)-0.12 ± 0.63-0.18 ± 0.710.00 ± 0.32
Week 4 (N= 148, 34, 18)-0.25 ± 0.64-0.24 ± 0.82-0.22 ± 0.43
Week 6 (N= 139, 31, 15)-0.40 ± 0.66-0.35 ± 0.80-0.33 ± 0.49
Week 8 (N= 20, 6, 2)-0.20 ± 0.770.17 ± 0.410.00 ± 0.00
Week 14 (N= 20, 6, 2)-0.40 ± 0.680.83 ± 1.600.50 ± 0.71
Week 20 (N= 20, 5, 2)-0.55 ± 0.760.20 ± 0.450.00 ± 0.00
Week 26 (N= 19, 5, 2)-0.63 ± 0.900.00 ± 0.710.00 ± 0.00
Week 32 (N= 18, 5, 2)-0.78 ± 0.810.20 ± 1.10-0.50 ± 0.71
Week 38 (N= 17, 3, 2)-0.71 ± 0.850.00 ± 0.00-0.50 ± 0.71
Week 44 (N= 17, 2, 2)-0.82 ± 0.810.00 ± 0.00-0.50 ± 0.71
Week 52 (N= 16, 2, 2)-0.88 ± 0.810.00 ± 0.00-0.50 ± 0.71
Last visit (N= 176, 41, 23)-0.33 ± 0.83-0.15 ± 1.20-0.30 ± 0.56
SecondaryChange From Baseline in Personal and Social Performance Scale (PSP) Total Score.

The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
Baseline, Week 1, 2, 6, 26, 52 and Last Visit
Reported as:
Median · Units on a scale
Change From Baseline in Personal and Social Performance Scale (PSP) Total Score.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Week 1 (N= 5, 1, 1)-2.00 ± 4.82-21.00 ± 0-5.00 ± 0
Week 2 (N= 163, 40, 21)1.00 ± 7.111.50 ± 8.160.00 ± 0.00
Week 6 (N= 139, 31, 15)5.00 ± 9.346.00 ± 10.861.00 ± 5.96
Week 26 (N= 19, 5, 2)6.00 ± 5.3512.00 ± 8.072.50 ± 3.54
Week 52 (N= 16, 2, 2)13.00 ± 7.3113.00 ± 1.410.50 ± 0.71
Last visit (N= 171, 41, 22)4.00 ± 10.285.00 ± 15.101.00 ± 5.32
SecondaryMean Clinical Global Impression- Improvement Scale (CGI-I) Total Score.

The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participants total improvement whether or not it was due to the drug treatment. All responses were compared to the participants condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression- Improvement Scale (CGI-I) Total Score.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Day 4 (N= 169, 36, 22)3.70 ± 0.873.56 ± 0.883.23 ± 1.15
Week 1 (N= 167, 40, 23)3.51 ± 0.893.73 ± 0.933.13 ± 1.14
Week 2 (N= 164, 40, 21)3.41 ± 1.103.45 ± 1.283.38 ± 1.28
Week 4 (N= 148, 34, 18)3.14 ± 1.043.26 ± 1.212.94 ± 1.21
Week 6 (N= 139, 31, 15)2.86 ± 0.993.03 ± 1.282.60 ± 1.18
Week 8 (N= 20, 6, 2)2.80 ± 0.953.50 ± 1.223.00 ± 1.41
Week 14 (N= 20, 6, 2)2.75 ± 0.853.83 ± 1.604.50 ± 0.71
Week 20 (N= 20, 5, 2)2.70 ± 1.033.20 ± 1.304.00 ± 0.00
Week 26 (N= 19, 5, 2)2.74 ± 0.933.00 ± 1.414.00 ± 0.00
Week 32 (N= 18, 5, 2)2.56 ± 0.783.20 ± 1.793.00 ± 1.41
Week 38 (N= 17, 3, 2)2.53 ± 0.872.67 ± 1.153.00 ± 1.41
Week 44 (N= 17, 2, 2)2.35 ± 0.793.00 ± 1.413.00 ± 1.41
Week 52 (N= 16, 2, 2)2.31 ± 0.793.00 ± 1.413.00 ± 1.41
Last visit (N= 176, 41, 23)3.04 ± 1.143.32 ± 1.522.83 ± 1.19
SecondaryChange From Baseline in PANSS Positive Subscale Score.

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive symptom score ranges from 7-49, with higher scores indicating more severe symptoms.

Time frame:
Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Positive Subscale Score.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Day 4 (N= 169, 36, 22)-0.04 ± 2.06-0.50 ± 1.360.09 ± 2.24
Week 1 (N= 167, 40, 23)-0.66 ± 1.91-0.25 ± 2.72-0.78 ± 2.76
Week 2 (N= 165, 40, 21)-1.09 ± 2.92-0.70 ± 3.75-0.05 ± 2.84
Week 4 (N= 148, 34, 18)-1.53 ± 2.96-1.06 ± 3.95-1.11 ± 2.08
Week 6 (N= 138, 31, 15)-2.36 ± 3.21-2.03 ± 3.06-1.87 ± 2.39
Week 8 (N= 20, 6, 2)-2.10 ± 3.02-1.67 ± 2.34-2.50 ± 2.12
Week 14 (20, 6, 2)-2.80 ± 2.652.17 ± 9.041.00 ± 4.24
Week 20 (20, 5, 2)-2.60 ± 3.49-1.80 ± 2.390.00 ± 4.24
Week 26 (N= 19, 5, 2)-3.42 ± 2.99-2.60 ± 2.61-3.00 ± 1.41
Week 32 (N= 18, 5, 2)-3.83 ± 3.54-1.00 ± 4.85-5.00 ± 1.41
Week 38 (N= 17, 3, 2)-3.71 ± 4.10-2.67 ± 2.52-3.00 ± 0.00
Week 44 (N= 17, 2, 2)-4.24 ± 3.53-1.50 ± 2.12-4.00 ± 1.41
Week 52 (N= 16, 2, 2)-3.63 ± 3.74-1.50 ± 2.12-4.50 ± 3.54
Last visit (N= 176, 41, 23)-1.74 ± 3.86-0.22 ± 6.04-1.43 ± 2.87
SecondaryChange From Baseline in PANSS Negative Subscale Score.

The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative symptom score ranges from 7-49, with higher scores indicating more severe symptoms.

Time frame:
Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Negative Subscale Score.
Units on a scalePrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Day 4 (N= 169, 36, 22)-0.01 ± 1.99-0.25 ± 1.00-0.86 ± 2.12
Week 1 (N= 167, 40, 23)-0.47 ± 2.15-0.40 ± 2.58-0.87 ± 2.44
Week 2 (N= 165, 40, 21)-0.68 ± 2.61-0.83 ± 2.32-1.19 ± 2.52
Week 4 (N= 148, 34, 18)-1.03 ± 2.99-1.35 ± 3.02-1.94 ± 2.48
Week 6 (N= 138, 31, 15)-1.70 ± 3.04-1.97 ± 2.70-2.40 ± 2.61
Week 8 (N= 20, 6, 2)-2.55 ± 2.68-1.00 ± 2.00-1.00 ± 1.41
Week 14 (N= 20, 6, 2)-2.85 ± 3.151.17 ± 7.05-1.50 ± 2.12
Week 20 (N= 20, 5, 2)-3.00 ± 3.04-0.60 ± 1.14-2.00 ± 2.83
Week 26 (N= 19, 5, 2)-3.74 ± 3.43-1.20 ± 1.48-2.50 ± 2.12
Week 32 (N= 18, 5, 2)-4.00 ± 4.41-1.00 ± 1.87-2.50 ± 3.54
Week 38 (N= 17, 3, 2)-3.94 ± 3.93-0.67 ± 2.08-2.50 ± 3.54
Week 44 (N= 17, 2, 2)-4.18 ± 3.61-1.00 ± 2.83-2.50 ± 3.54
Week 52 (N= 16, 2, 2)-4.00 ± 3.58-1.00 ± 2.83-2.00 ± 1.41
Last visit (N= 176, 41, 23)-1.53 ± 3.28-1.10 ± 3.85-2.09 ± 2.59
SecondaryPercentage of Participants With a Positive Response Rate.

Response rate was defined as a reduction of ≥ 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit.

Time frame:
Last Visit
Reported as:
Number · Percentage of participants
Percentage of Participants With a Positive Response Rate.
Percentage of participantsPrior BrexpiprazolePrior PlaceboPrior Aripiprazole
Percentage of Participants With a Positive Response Rate.33.536.645.8
SecondaryPercentage of Participants Who Discontinued Due to Lack of Efficacy.

Discontinuation rate for the participants discontinued due to lack of efficacy were examined.

Time frame:
Last Visit
Reported as:
Number · Percentage of participants.
Percentage of Participants Who Discontinued Due to Lack of Efficacy.
Percentage of participants.Prior BrexpiprazolePrior PlaceboPrior Aripiprazole
Percentage of Participants Who Discontinued Due to Lack of Efficacy.2.80.00.0

Adverse events

Collected over AEs were recorded from Screening (ICF was signed) to Follow-up 30 (± 2) days, up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Brexpiprazole—4/178 (2.2%)31/178 (17.4%)
Prior Placebo—6/41 (14.6%)10/41 (24.4%)
Prior Aripiprazole—1/23 (4.3%)4/23 (17.4%)
Most frequent serious events
Most frequent serious events
EventPrior BrexpiprazolePrior PlaceboPrior Aripiprazole
SchizophreniaPsychiatric disorders2/1783/410/23
Psychotic disorderPsychiatric disorders2/1781/411/23
BronchitisInfections and infestations0/1781/410/23
InfluenzaInfections and infestations0/1781/410/23
ConvulsionNervous system disorders0/1781/410/23
Most frequent other events
Most frequent other events
EventPrior BrexpiprazolePrior PlaceboPrior Aripiprazole
HeadacheNervous system disorders6/1785/410/23
Extrapyramidal disorderNervous system disorders2/1781/412/23
AnxietyPsychiatric disorders5/1780/412/23
InsomniaPsychiatric disorders10/1783/410/23
TremorNervous system disorders9/1781/410/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Prior BrexiprazolePrior PlaceboPrior ApripiprazoleTotal
Mean39.1 ± 10.141.4 ± 11.241.2 ± 1239.7 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Prior BrexiprazolePrior PlaceboPrior ApripiprazoleTotal
Female6917591
Male1102419153
08

Study locations

71 sites
  • Otsuka Investigational Site
    Little Rock, Arkansas 72211, United States
  • Otsuka Investigational Site
    Escondido, California 92025, United States
  • Otsuka Investigational Site
    Garden Grove, California 92845, United States
  • Otsuka Investigational Site
    Long Beach, California 90813, United States
  • Otsuka Investigational Site
    Oceanside, California 92056, United States
  • Otsuka Investigational Site
    Pasadena, California 91106, United States
  • Otsuka Investigational Site
    San Diego, California 92102, United States
  • Otsuka Investigational Site
    San Diego, California 92123, United States
  • Otsuka Investigational Site
    Santa Ana, California 92701, United States
  • Otsuka Investigational Site
    Washington, District of Columbia 20016, United States
  • Otsuka Investigational Site
    Bradenton, Florida 34208, United States
  • Otsuka Investigational Site
    Maitland, Florida 32751, United States
  • Otsuka Investigational Site
    St. Louis, Missouri 63118, United States
  • Otsuka Investigational Site
    Cedarhurst, New York 11516, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19139, United States
  • Otsuka Investigational Site
    Austin, Texas 78731, United States
  • Otsuka Investigational Site
    Burgas, 8000, Bulgaria
  • Otsuka Investigational Site
    Kazanlak, 6100, Bulgaria
  • Otsuka Investigational Site
    Pazardzhik, 4400, Bulgaria
  • Otsuka Investigational Site
    Plovdiv, 4002, Bulgaria
  • Otsuka Investigational Site
    Radnevo, 6260, Bulgaria
  • Otsuka Investigational Site
    Ruse, 7003, Bulgaria
  • Otsuka Investigational Site
    Rijeka, 51 000, Croatia
  • Otsuka Investigational Site
    Zagreb, 10 090, Croatia
  • Otsuka Investigational Site
    Vijaywada, Andh Prad 520002, India
  • Otsuka Investigational Site
    Visakhapatnam, Andh Prad 530017, India
  • Otsuka Investigational Site
    Ahmedabad, Gujarat 380015, India
  • Otsuka Investigational Site
    Bangalore, Karna 560010, India
  • Otsuka Investigational Site
    Mangalore, Karna 575001, India
  • Otsuka Investigational Site
    Mangalore, Karna 575018, India
  • Otsuka Investigational Site
    Pune, Mahara 411 004, India
  • Otsuka Investigational Site
    Chennai, Tamilnadu 600003, India
  • Otsuka Investigational Site
    Varanasi, Uttar Prad 221005, India
  • Otsuka Investigational Site
    Chuncheon, 200-704, Korea, Republic of
  • Otsuka Investigational Site
    Incheon, 400-711, Korea, Republic of
  • Otsuka Investigational Site
    Incheon, 405-760, Korea, Republic of
  • Otsuka Investigational Site
    Seoul, 143-711, Korea, Republic of
  • Otsuka Investigational Site
    Cebu City, 6000, Philippines
  • Otsuka Investigational Site
    Mandaluyong City, 1553, Philippines
  • Otsuka Investigational Site
    Arad, 310022, Romania
  • Otsuka Investigational Site
    Bucuresti 2, 041914, Romania
  • Otsuka Investigational Site
    Bucuresti 3, 041914, Romania
  • Otsuka Investigational Site
    Bucuresti, 010825, Romania
  • Otsuka Investigational Site
    Bucuresti, 041914, Romania
  • Otsuka Investigational Site
    Cluj - Napoca, 400012, Romania
  • Otsuka Investigational Site
    Oradea, 410154, Romania
  • Otsuka Investigational Site
    Moscow Region, 141371, Russian Federation
  • Otsuka Investigational Site
    Moscow, 115522, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 190121, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 193167, Russian Federation
  • Otsuka Investigational Site
    St. Petersburg, 197341, Russian Federation
  • Otsuka Investigational Site
    Zagorodnoye, 117152, Russian Federation
  • Otsuka Investigational Site
    Belgrade 2, 11000, Serbia
  • Otsuka Investigational Site
    Belgrade, 11000, Serbia
  • Otsuka Investigational Site
    Kragujevac, 34000, Serbia
  • Otsuka Investigational Site
    NoviSad, 21000, Serbia
  • Otsuka Investigational Site
    Bojnice, 92701, Slovakia
  • Otsuka Investigational Site
    Bratislava, 82606, Slovakia
  • Otsuka Investigational Site
    Liptovsky Mikulas, 03123, Slovakia
  • Otsuka Investigational Site
    Rimavska Sobota, 97912, Slovakia
  • Otsuka Investigational Site
    Zilina, 01207, Slovakia
  • Otsuka Investigational Site
    Hualian, 981, Taiwan
  • Otsuka Investigational Site
    Taipei, 249, Taiwan
  • Otsuka Investigational Site
    Chernigiv, 14005, Ukraine
  • Otsuka Investigational Site
    Dnipropetrovsk, 49005, Ukraine
  • Otsuka Investigational Site
    Kyiv, 02660, Ukraine
  • Otsuka Investigational Site
    Kyiv, 04080, Ukraine
  • Otsuka Investigational Site
    Kyiv, 04655, Ukraine
  • Otsuka Investigational Site
    Simferopol, 95006, Ukraine
  • Otsuka Investigational Site
    Stepanivka, 73488, Ukraine
  • Otsuka Investigational Site
    Vinnytsya, 21005, Ukraine
09

References and documents

Publications

  • Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14. PubMed 27188270 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Aug 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 4 years 2 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2012
First posted
Jul 25, 2012
Start
Aug 2009
Primary completionActual
Aug 2011
CompletionActual
Sep 2011
Results delay requested
Sep 4, 2012
Results first posted
Oct 29, 2015
Last update
Oct 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01649557
Responsible party
Sponsor
First posted
Jul 25, 2012
Start date
Aug 2009
Primary completion
Aug 2011
Completion
Sep 2011
Results posted
Oct 29, 2015
Last update
Oct 29, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion